Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin

Current Medical Research and Opinion

Volumn 20, Issue 5, 2004, Pages 749-756

  Niederman, Michael S ^a   Chang, Joanne R ^b   Stewart, John ^c   Nusrat, Roomi ^b   Nieman, Richard B ^b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b SANOFI   (France)

^c Aventis Pharma   (Canada)

Author keywords

Clarithromycin; Community acquired pneumonia; Healthcare resource utilization; Hospitalization; Telithromycin

Indexed keywords

CLARITHROMYCIN; TELITHROMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; KETOLIDES; MACROLIDES; MALE; MIDDLE AGED; PNEUMONIA; TREATMENT OUTCOME;

EID: 2542424466     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125003601     Document Type: Article

References (26)

1. Gant V, Parton S. Community-acquired pneumonia. Curr Opin Pulm Med 2000;6:226-33
2. Bartlett JG, Breiman RF, Mandell LA, File Jr. TM. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811-38
3. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820-37
4. Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics 2002;20:513-28
5. Marston BJ, Plouffe JF, File Jr. TM, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch Intern Med 1997;157:1709-18
6. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54
7. Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med 1985;78(Suppl 6B):45-51
8. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults: incidence, epidemiology, and impact. Am J Med 1985;78:32-7
9. Spiritus EM, Chang RJ, Zhang JX, et al. Cost savings of clarithromycin compared with erythromycin or cefaclor in the treatment of lower respiratory tract infection: results of a randomized, multicenter study. Am J Manag Care 1998;4(Suppl 10):S562-S570
10. Mandell LA. Community-acquired pneumonia. Etiology, epidemiology, and treatment. Chest 1995;108(Suppl 2):S35-S42
11. Bernstein JM. Treatment of community-acquired pneumonia - IDSA guidelines. Chest 1999;115(Suppl):9S-13S
12. Mandell LA, Bartlett JG, Dowell SF, File Jr. TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Infectious Diseases Society of America. Clin Infect Dis 2003;37:1405-33
13. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399-408
14. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421
15. Felmingham D, Grüneberg RN, The Alexander Project Group. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000;45:191-203
16. Balfour JA, Figgitt DP. Telithromcyin. Drugs 2001;61:815-2
17. Zhanel GG, Walters M, Noreddin A, et al. The ketolides: a critical review. Drugs 2002;62:1771-804
18. Carbon C. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults. Infection 2003;31:308-17
19. Aventis. Ketek (telithromycin). Briefing document for the FDA anti-infective drug products advisory committee meeting, January 2003. Available from http://www.fda.gov/ohrms/dockets/ac/03/briefing/3919B1_01_Aventis-KETEK.pdf [Accessed 27] November 2003]
20. Dunbar LM, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004;26:48-62
21. Tellier G, Isakov T, Petermann W, Patel M, Lavin B. Efficacy and safety of telithromycin for 5 or 7 days vs clarithromycin for 10 days in the treatment of patients with community-acquired pneumonia [Abstract L373]. In: Abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology; 2002
22. Tellier G, Chang JR, Asche CV, Lavin B, Stewart J, Sullivan SD. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. Curr Med Res Opin 2004;20(5):739-47
23. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl J Med 1997;336:243-50
24. American Hospital Association. Hospital Statistics. Data derived from responses to the 1999 American Hospital Association Annual Survey. In: Hospital statistics, 2001 ed. Chicago: Health Forum LLC, an affiliate of the American Hospital Association; 2001
25. Mandell L, Chang J, Oster G, et al. Comparison of healthcare utilization in patients with acute exacerbations of chronic bronchitis (AECB) receiving telithromycin (TEL) versus clarithromycin (CLA) in a randomized, double-blind, multicenter clinical trial [Abstract L1595]. In: Abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology; 2003
26. Chang JR, Stewart J, Cadilhac M, Nieman RB. Telithromycin (TEL) results in fewer hospitalizations than amoxicillin-clavulanate (AMC) in the outpatient treatment of acute exacerbations of chronic bronchitis (AECB). Value Health 2003;6:250-1